tldrdaily.news logo

FDA Approves Breakthrough RSV Drug to Safeguard Infants and Toddlers

1 min read
Source: FDA.gov
FDA Approves Breakthrough RSV Drug to Safeguard Infants and Toddlers
Photo: FDA.gov
TL;DR Summary

The FDA has approved Beyfortus (nirsevimab-alip), a new drug developed by AstraZeneca, for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates, infants, and children up to 24 months of age. RSV can cause serious respiratory infections in infants and young children, leading to hospitalizations. Beyfortus is a monoclonal antibody that provides protection against RSV when administered as a single intramuscular injection prior to or during RSV season. Clinical trials showed that Beyfortus reduced the risk of medically attended RSV lower respiratory tract infection by approximately 70% to 75% compared to placebo. Possible side effects include rash and injection site reactions.

Topics:business#beyfortus#fda#health#infants#respiratory-tract-disease#rsv
Share this article
  1. FDA Approves New Drug to Prevent RSV in Babies and Toddlers  FDA.gov
  2. FDA approves antibody to protect infants from RSV  CNN
  3. FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV  CNBC
  4. FDA Approves First RSV Drug to Protect All Infants From Virus  The Wall Street Journal
  5. FDA approves RSV monoclonal antibody for infants, young children at high risk  STAT
  6. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

4 min

vs 5 min read

Condensed

87%

824 → 105 words

Want the full story? Read the original article

Read on FDA.gov